Combo Therapy for Myelodysplastic Syndromes Misses Survival Goal in Randomized Trial

(MedPage Today) — HOUSTON — Survival in untreated, intermediate- and higher-risk myelodysplastic syndromes (MDS) failed to improve with the addition of the targeted agent venetoclax (Venclexta) to chemotherapy, a large randomized trial showed…